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Abstract 
The NOD-like receptor family, pyrin domain-containing 3 (NLRP3) inflammasome is the best 
recognized and most widely implicated regulator of caspase-1 activation. It is a key regulator of 
innate immune response and is involved in many pathophysiological processes. Recent evidences 
for its inappropriate activation in autoinflammatory, autoimmune, as well as in neurodegenerative 
diseases attract a growing interest toward the development of small molecules NLRP3 inhibitors. 
Based on the knowledge of biochemical and structural aspects of NLRP3 activation, one successful 
strategy in the identification of NLRP3 inhibitors relies on the development of covalent irreversible 
inhibitors. Covalent inhibitors are reactive electrophilic molecules able to alkylate nucleophiles in 
the target protein. These inhibitors could ensure good efficacy and prolonged duration of action 
both in vitro and in vivo. In spite of these advantages, effects on other signaling pathways, prone to 
alkylation, may occur. In this review, we will illustrate the chemistry and the biological action of 
the most studied covalent NLRP3 inhibitors developed so far. A description of what we know about 
their mechanism of action will address the reader toward a critical understanding of NLRP3 
inhibition by electrophilic compounds.   
4 
 
 
Contents 
 
1. Introduction 
2. An overview of NLRP3 inflammasome activation and signaling 
3. The NLRP3 inflammasome as a drug target: structural biology and conformational changes 
4. Blocking the NLRP3 inflammasome with covalent inhibitors 
5. (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile (BAY 11-7082) 
6. 3,4-methylenedioxy-β-nitrostyrene (MNS) 
7. Ethyl 2-(2-Chlorobenzyl)acrylate (INF39) and other acrylic acid derivatives (INF compounds) 
8. 5-Acetyl-6-amino-2,2-diphenyl-4-(trichloromethyl)-2,3-dihydro-1,3,2-oxazaborinin-1-ium-2-
uide (NBC6) and related cyclic diaryl boron derivatives 
9. (Z)-4-((4-Oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic 
acid (CY-09) 
10. Dimethyl fumarate (DiMF) and monomethyl fumarate (MMF) 
11. N-(3’,4’-dimethoxycinnamoyl)-anthranilic acid (Tranilast) 
12. 2-cyclohexylimino-6-methyl-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one (BOT-4-one) 
13. (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide (WP1066) 
14. Caffeic acid phenylethyl ester (CAPE) 
15. Other electrophilic NLRP3 inhibitors  
16. Concluding remarks 
References 
  
5 
 
1. Introduction 
The nucleotide-binding oligomerization domain (NOD)-like receptor family, pyrin domain-
containing 3 (NLRP3 or NALP3) is a cytosolic pattern recognition receptor (PRR) that senses 
exogenous and endogenous danger signals. Other PRR capable of forming an inflammasome 
complex are known, among them the most studied are the NLRP1 (NLR family, pyrin domain-
containing 1), the NLRC4 (NLR family, CARD domain-containing 4) and the AIM2 (absent in 
melanoma 2) inflammasomes [1]. The NLRP3 protein is made up of three domains: a leucine-rich 
repeat domain (LRR), a nucleotide binding oligomerisation domain containing a CARD (caspase 
activation and recruitment domain) (NACHT), and a pyrin domain (PYD). Upon activation, NLRP3 
oligomerises and triggers the helical fibrillar assembly of the adapter apoptosis-associated speck-
like protein containing a CARD (ASC) via PYD–PYD interactions. ASC fibrils assemble into large 
structures, called ASC specks, and recruit pro-caspase-1, leading to its autoproteolytic activation. 
The activated caspase-1 is able to cleave pro-interleukin(IL)-1β and pro-IL-18 to generate the 
inflammatory cytokines IL-1β and IL-18 [1,2]. Moreover, activated caspase-1 is also able to cleave 
gasdermin-D (GSDMD) to its active form (GSDMD-N), depending on cell type, thus triggering 
programmed cell death, called pyroptosis [3]. 
The assembled NLRP3 inflammasome plays a key role in the innate immune system. While acute 
inflammatory conditions are a physiological response to host infection and cellular damage, chronic 
inflammation is detrimental and can cause secondary damage to cells and host tissues. NLRP3 
inflammasome component overexpression and/or NLRP3 inflammasome over-activation have been 
reported as occurring in many pathological conditions. NLRP3 inflammasome complexes have been 
identified in several human peripheral and brain tissues, in both in vivo and ex vivo work. A review 
that explores inflammasome expression, distribution and activation in a variety of human 
inflammasomopathies (i.e. autoinflammatory disease caused by inflammasome activity disruption) 
has been recently published [4]. 
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Gain-of-function mutations in the nlrp3 gene have been associated with autoinflammatory diseases, 
including cryopyrinopathies (Cryopyrin-associated periodic syndromes; CAPS), which are a case in 
point [5-8]. CAPS are caused by an autosomal dominant mutation in NLRP3 [9]. The term CAPS 
encompasses three diseases: familial cold autoinflammatory syndrome (FCAS), Muckle–Wells 
syndrome (MWS) and neonatal-onset multisystem inflammatory disease (NOMID), the latter of 
which is also known as chronic infantile neurologic cutaneous articular (CINCA) syndrome [10-
12]. These auto-inflammatory diseases generally display neonatal onset and cause a large spectrum 
of symptoms, ranging from periodic fevers and altered joint/skeletal development to neurological 
disorders [13].  
Observations that uric acid crystals activate the NLRP3 inflammasome led to gout being the first 
chronic NLRP3-driven inflammatory disorder investigated. While that study was performed by 
Tschopp’s group back in 2006 [14], other pathologies have since been associated with NLRP3 over-
activation. Increased NLRP3 response, followed by IL-1β release (and in some cases pyroptotic cell 
death), has been reported in chronic inflammatory and autoimmune diseases, such as inflammatory 
bowel disease (IBD), ulcerative cholitis (UC) and Crohn’s disease (CD) [15-17], non-alcoholic 
steatohepatitis (NASH) [18], psoriasis [19], autoimmune encephalomyelitis and multiple sclerosis 
[20]. 
The pro-inflammatory role played by the NLRP3 inflammasome has also been demonstrated in 
various rheumatic diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis 
(RA), systemic-onset juvenile idiopathic arthritis (s-JIA), adult-onset Still’s disease (AOSD) and 
crystal arthropathies, such as pseudogout [21-23].  
The overexpression of NLRP3 and the activation of the NLRP3-mediated inflammatory response 
has been observed in recent years in several neurodegenerative diseases [24,25], such as 
amiotrophic lateral sclerosis (ALS) [26], Alzheimer’s disease [27-29] and Parkinson’s disease [30-
31]. 
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Metabolic and vascular diseases, such as Type 2 diabetes (T2D) and atherosclerosis, have also been 
linked to NLRP3 overactivation [32-36]. The therapeutic value of NLRP3 inhibition - the 
dampening of inflammatory responses in animal models of myocardial infarction using a variety of 
experimental NLRP3 inhibitors - has been demonstrated in several studies [37]. 
It is worth noting that the beneficial outcomes of blocking IL-1β effects in cardiovascular diseases 
have recently been demonstrated in the Canakinumab Anti-inflammatory Thrombosis Outcomes 
Study (CANTOS), which is a clinical trial that has enrolled 10,061 patients with inflammatory 
atherosclerosis and a prior history of heart attacks [38]. A seminal paper by Latz’s group has very 
recently linked western diet-promoted NLRP3 inflammasome activation to the epigenomic 
reprogramming of myeloid progenitor cells. This finding opens up new possibilities as to the 
complex role played by the NLRP3 inflammasome in a number of metabolic and immune-mediated 
diseases [39-42]. 
Finally, the NLRP3 inflammasome, together with other inflammasomes, influences the 
pathogenesis of cancer by modulating innate and adaptive immune responses, cell death, 
proliferation and/or the gut microbiota. Excessive inflammation, driven by the inflammasome or the 
IL-1β signalling pathways, promotes breast cancer, fibrosarcoma, gastric carcinoma and lung 
metastasis in a context-dependent manner [43,44]. These observations have been further 
corroborated by CANTOS trial findings, which also observed 67 % reduction in lung cancer 
incidence and 77 % reduction in death from lung cancer in canakinumab-treated patients [45]. The 
relevance of inflammasomes in multiple forms of cancer might hold promise for the development of 
a new class of antitumor and anti-metastatic agents that can act on new molecular targets.  
Pharmacological agents that function as IL-1β blocking drugs have already been developed. 
Anakinra, canakinumab, and rilonacept are clinically available biological IL-1β blockers acting 
through different mechanisms of action. Although these drugs are quite effective, they have several 
drawbacks: (i) they only target IL-1β response and have no influence on IL-18-mediated effects or 
pyroptotic cell death-driven inflammation; (ii) they are peptides, meaning that their 
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pharmacokinetics do not allow for oral administration or blood-brain barrier penetration, thus 
limiting their use to the treatment of peripheral diseases; (iii) they might increase the risk of 
opportunistic infections; (iv) they are expensive. The development of small molecule NLRP3 
inhibitors would therefore be preferable and provide us with the possibility of developing drugs that 
can inhibit all NLRP3-mediated responses, be administered orally, and that are cheaper than 
biological IL-1β blockers. In light of the above, it is not surprising that interest in the NLRP3 
inflammasome as a drug target is growing rapidly and medicinal chemists have begun to study the 
possibility of inhibiting the NLRP3 inflammasome as a new treatment strategy. While specifically 
designed NLRP3 inhibitors have yet to reach the drug market, a number of small molecule 
inhibitors of the NLRP3 inflammasome have been developed [46,47]. 
This review will focus on the medicinal chemistry of covalent NLRP3 inhibitors. 
 
2. An overview of NLRP3 inflammasome activation and signalling 
The NLRP3 inflammasome molecular mode of activation remains to be fully defined, however, 
recent studies have greatly enhanced our understanding of the mechanism. The mechanisms 
underlying NLRP3 inflammasome activation and signalling are reviewed elsewhere in this issue, 
and will therefore only be briefly summarized herein (Figure 1) with the scope of illustrating the 
point of intervention of various NLRP3 blockers that are the object of this review. 
NLRP3 inflammasome works as a highly sensitive, but non-specific, surveillance mechanism that 
responds to any type of perturbation that breaches plasma membrane integrity and the associated K+ 
gradient across the membrane [48-51]. As the NLRP3 inflammasome is an important regulation 
checkpoint for innate immune defence, its activation usually requires two different signals in order 
to prevent superfluous inflammation, which can be deleterious for the host. These signals are 
generally referred to as the priming signal (signal 1) and the activation signal (signal 2). However, 
while two signals are necessary in dendritic cells and macrophages, only one signal is sufficient for 
NLRP3 activation in monocytes, which, in fact, need to be highly reactive. An alternative 
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inflammasome activation can occur in monocytes and can lead to the release of inflammatory IL-1β 
without triggering pyroptosis [48]. 
During the priming step transcriptional regulation of gene expression is promoted leading to the 
increase of NLRP3 and pro-IL-1β levels in the cell. Instead, transcriptional regulation is not 
required for ASC, procaspase-1 and pro-IL-18, which are available in sufficient amount in cell 
cytoplasm in basal conditions [52]. The crucial up-regulator for NLRP3 and pro-IL-1β is the 
transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), which is 
activated upstream via the stimulation of numerous cytokine receptors, such as Toll-like receptors 
(TLRs), IL-1 receptor 1 (IL-1R1), NOD-like receptors (NLRs), tumor necrosis factor receptor 1 and 
2 (TNFR1, TNFR2). Signalling from cytokines receptors proceeds through either myeloid 
differentiation primary response 88 (MyD88) or TIR (Toll/IL-1 receptor) domain-containing 
adapter-inducing interferon-β (TRIF), followed by certain IL-1R-associated kinase (IRAK) family 
members. IRAK1 and IRAK4 seem to be specifically responsible for activation of inhibitor of NF-
kB kinase (IKK) and downstream NF-κB phosphorylation. This signal is essential for NF-κB 
migration into the nucleus and transcriptional activation to occur. 
Once expressed, free cytosolic NLRP3 is maintained in an inactive status thanks to the 
ubiquitination of its LRR domain, therefore, deubiquitinylation is required prior to its activation. 
Inhibition of deubiquitinating (DUB) activity of BRCC3 (JAMM domain-containing Zn2+ 
metalloprotease DUBs) inhibits the subsequent activation of NLRP3 [53]. Recent studies have 
reported that host-derived factors may prime the inflammasome during sterile inflammatory 
diseases, such as atherosclerosis, metabolic diseases and neuroinflammatory disorders [54]. 
The activation step is elicited by several stimuli, ranging from exogenous dangers (i.e. bacterial 
pathogens and pore-forming toxins) to endogenous molecules, such as crystals, aberrant proteins (e.g. 
amyloid-β peptide or α-synuclein aggregates), and ATP, the latter acting via interaction with the P2X7 
receptor. Considering the diversity among these activation signals, several studies have been 
conducted to identify common downstream effector(s) for NLRP3 activation. The main mechanisms 
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for NLRP3 activation include: potassium efflux, ROS production, lysosomal damage, and altered 
calcium signalling [52]. The role of volume-regulated anion channels (VRAC)-mediated chloride 
efflux in NLRP3 activation has recently been demonstrated in an investigation that worked with 
fenamate derivatives in both immortalized bone-marrow derived macrophages (iBMDMs) and THP-
1 cells [55]. As a matter of fact, a reduction of intracellular K+ concentration is sufficient to activate 
the NLRP3 inflammasome [50]. Potassium efflux has been proposed as a common trigger for NLRP3 
activation in response to different stimuli. Recent studies report the involvement of NEK7, a Ser/Thr 
kinase involved in mitotic cell division, in the sensing of low intracellular K+ [56]. NLRP3 associates 
with the catalytic domain of NEK7 in a K+-efflux dependent manner, to form a high-molecular-mass 
NLRP3-NEK7 complex, which triggers ASC oligomerization [57]. NEK7 might also have a role in 
mutant NLRP3 found in CAPS where some mutations can promote binding between NEK7 and 
NLRP3 [58]. Other activating stimuli, such as bacterial pore-forming toxins, nigericin, ATP, 
particulate matter, ROS, lysosomal damage, among others, cause K+ efflux, mitochondrial 
perturbation and/or the opening of large membrane pores [51]. 
After exposure to a danger signal, presumably recognized via LRR domain, NLRP3 monomers induce 
self-oligomerisation through the PYD-PYD interactions of ASC. Activated NLRP3-ASC specks 
recruits and oligomerises procaspase-1, which, activated by proximity-induced auto-cleavage, 
triggers proteolytic maturation of pro-IL-1β and pro-IL-18 [48,59,60].  
Other routes for the activation of the NLRP3 inflammasome, namely non-canonical and alternative 
inflammasome activation have been recently proposed [61]. Non-canonical NLRP3 inflammasome 
activation is strictly correlated with gram-negative infection or in vitro lipopolysaccharide (LPS)-
stimulation. LPS is a ligand of the TLR4 receptor, which triggers NF-κB-mediated NLRP3 and pro-
IL-1β expression. Studies on TLR4-deficient mice, showed only partial abrogation of NLRP3 
activation in the absence of TLR4-mediated priming activity. This finding suggested that a different 
kind of activation could be mediated by LPS [62]. Gram-negative bacteria secrete LPS-loaded 
outer-membrane vesicles (OMVs), delivering LPS into the host cytosol [63,64]. Caspase-11 can be 
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activated by direct binding of the hexa-acylated lipid A moiety of LPS, secreted by certain gram-
negative bacteria (E. coli, S. flexneri, S. typhimurium) via its CARD domain. Humans lack the 
caspase-11, but caspase-4 and caspase-5 are capable to bind intracellular LPS [65,66], thereby 
promoting non-canonical NLRP3 activation. 
The mechanisms of alternative NLRP3 inflammasome activation remain unclear, but evidence has 
pointed to a K+-independent direct activation of NLRP3 under LPS stimulation. This signalling 
pathway involves TLR4 in LPS-recognition, TRIF, RIPK-1 (receptor-interacting serine/threonine-
protein kinase 1), FADD (Fas-associated protein with death domain), while caspase-8 is the final 
effector that directly activates NLRP3 through a still-unknown mechanism. Moreover, the 
alternative activation does not require GSDMD as pyroptotic effector [67,68]. 
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Figure 1. A simplified view of the NLRP3 inflammasome signaling pathways. Blue arrows indicate 
main activation signals. The points of intervention of NLRP3 inhibitors that are described in this 
review are indicated in red. In the case of multi-target inhibition the most relevant mechanism is 
indicated with bold inhibitor name; accessory mechanisms of action are indicated in plain text. 
DAMP (danger-associated molecular patterns), PAMP (pathogen-associated molecular patterns)  
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3. The NLRP3 inflammasome as a drug target: structural biology and conformational 
changes. 
Whatever stimulus triggers NLRP3 inflammasome activation, conformational changes are required 
in the switch from the inactive resting conformation to the active structure that, in its turn, can trigger 
the downstream cascade. An event that promotes an activating change in NLRP3 conformation is 
potassium efflux. Bioluminescence Resonance Energy Transfer (BRET) studies have confirmed the 
importance of this step in changing NLRP3 into a shape that is ready for signalling [49,69]. These 
studies have also provided precious insight into the resting position of NLRP3. NLRP3 forms 
preassembled complexes, as is confirmed by the close proximity of NLRP3-PYD to NLRP3-LRR 
before stimulation. These studies highlight the essential nature of the NACHT domain in the 
formation of resting complexes. 
ATPase activity within the NACHT domain is also mandatory for NLRP3 inflammasome activation. 
NLRP3 actually needs to cleave ATP into ADP in its ATPase pocket in order to achieve the active 
conformation [70]. NLRP3 ATPase activity is required for oligomerisation, interaction with ASC and 
IL-1β release in WT-NLRP3, as well as in CAPS-mutated NLRP3. This suggests that blocking 
ATPase activity might be a feasible strategy with which to target cryopyrinopathies [7, 71]. 
All NLRP, including NLRP3, belong to the STAND (signal transduction ATPases with numerous 
domains) subfamily of AAA+ (ATPases associated with diverse cellular activities). Conserved motifs 
of the STAND family include an ATPase-specific P-loop, a Mg2+ coordinating loop, as well as 
Walker A and Walker B motifs [71]. While no crystal structures are available for any of the NACHT 
domains of the NLRP family, their similarity with APAF-1 (apoptotic protease activating factor-1) 
and NLRC4 (NLR family CARD domain-containing protein 4), whose structures have recently been 
solved, allows structural comparisons to be performed [72,73]. Sequence analyses show high 
conservations in the Walker A, Walker B, Sensor 1, and Sensor 2 motifs (Figure 2). The conserved 
Walker A motif is characterized by GxxGxGK(S/T), where the lysine residue (K) is crucial for direct 
interaction with the γ-phosphate of ATP. Walker B presents a conserved acidic residue (Asp or Glu) 
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in the hhhhDE motif, characterized by two consequent acidic residues, which coordinates Mg2+ and 
a molecule of water in a process that is necessary for hydrolysis. Sensor 1, characterized by three 
hydrophobic amino acids followed by two Ser/Thr residues that are followed by Arg, contributes to 
the perfect interaction between Walker A and Walker B and the correct positioning of the nucleotide. 
Sensor 2 is marked by the presence of a conserved Lys or Arg residue, which is responsible for 
nucleotide coordination, hydrolysis and conformational changes between subunits. It is worth 
highlighting two regions when comparing APAF-1 and NLRP3: a hydrophobic cluster in the N-
terminal of NACHT, and a GxP motif in the C-terminal where the proline is likely to play a crucial 
role in nucleotide stabilisation [71]. Of the numerous interesting van der Waals interactions, Ser325 
in APAF-1 and Trp416 in NLRP3 are particularly important as these residues are part of a Cys-rich 
motif VCWxVCT that is adjacent to the nucleotide binding site, which is crucial for nucleotide 
recognition [74]. In silico studies have demonstrated that the surroundings of the nucleotide binding 
sites in NLRP3 consist of Gly229, Ile230, Gly231, Lys232, Thr233 and Ile234, that are oriented 
around α- and β-phosphates of ADP. All of these considerations and similarities with Ser/Thr kinase 
pockets might assist in the development of drugs that disrupt binding with ATP. Two types of ATPase 
inhibitors can be designed: they are generally defined as type 1 (that occupy ATP-binding sites in the 
active conformation) or type 2 inhibitors (allosteric modulators of sites adjacent to the ATP pocket).  
Other domains of NLRP3 and its interacting proteins (such as ASC) need to change conformations 
to start inflammasome signalling. PYD-PYD interactions might also cause relevant conformational 
changes [75], as might ASC-ASC interactions [76]. The PYD domain might play a role as the 
formation of a disulphide bridge between Cys8 and Cys108 has been observed in the active 
conformation of NLRP3 [77]. The structural mechanisms involved in NLRP3 inflammasome 
formation have recently been reviewed and are still a matter of investigation [78,79]. 
Finally, post-translational phosphorylation plays a complex role in the regulation of NLRP3 
assembly. Protein-kinase A (PKA) is able to phosphorylate Ser295 in the NACHT domain in already 
assembled inflammasome, thus inducing inflammasome disassembly [80]. Several recognized 
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CAPS-related mutations are detected in the NACHT domain that are capable of switching off the 
regulatory phosphorylation of Ser295 [7]. Phosphorylation at Ser5 in the PYD domain is also capable 
to hamper inflammasome activation by abrogating PYD-PYD interaction [81]. 
 
 
 
Figure 2. Human NLRP3 sequence (www.uniprot.org/uniprot/Q96P20). Walker A (227-234), 
Walker B (296-302), Sensor 1 (346-351), and Sensor 2 (365-368) in the NACHT domain (red) are 
reported in bold capital letters. 
 
 
4. Blocking the NLRP3 inflammasome with covalent inhibitors 
Experimental work on the identification of molecules that are able to act as NLRP3 inhibitors has 
been performed since NLRP3 inflammasome’s discovery in 2002 by Tschopp’s group [82]. It is 
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interesting to note that, even before it was discovered, scientists at Pfizer had already identified that 
the approved drug glyburide and other sulfonylurea derivatives (Figure 3) were able to block IL-1β 
release in human monocytes following LPS/ATP stimulation [83]. Glyburide and sulfonylurea 
derivatives that share the ability to block IL-1β release, collectively named CRIDs (cytokine release 
inhibitory drugs), have been the object of extensive research [84,85], which has led to the selection 
of MCC950, also known as CRID3 or CP-456,773 (Figure 3), as a potent NLRP3 blocker [86]. 
 
 
 
Figure 3. Structure of Cytokine release inhibitory drugs (CRIDs) 
 
 
Two papers, published in 2010, demonstrated that the synthetic small molecule BAY 11-7082, 
parthenolide, a natural sesquiterpene lactone isolated from Tanacetum parthenium, and bromoxone, 
a natural product isolated from a species of acorn worms [87] (Figure 4), were able to prevent 
NLRP3-dependent pyroptosis and to inhibit the release of IL-1β from phorbol 12-myristate 13-
acetate (PMA)-differentiated THP-1 cells after LPS/ATP stimulation [88,89]. In 2014, He et al. 
published a paper showing that 3,4-methylenedioxy-β-nitrostyrene (MNS; Figure 4), a synthetic 
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kinase inhibitor, was able to block NLRP3 assembly via the direct targeting of NLRP3 ATPase 
activity [90]. 
As reported above, most of the early discoveries identified structurally unrelated compounds as 
direct/indirect NLRP3 inhibitors. With the notable exception of CRIDs, they are all electrophilic 
derivatives that bear a Michael acceptor moiety in their structure (Figure 4).  
 
 
 
Figure 4. Structures of electrophilic NLRP3 inhibitors BAY-11708, parthenolide, bromoxone, and 
MNS. The Michael acceptor moiety is written in red. 
 
 
Michael acceptors are able to react with the biological nucleophilic residues, such as cysteine, 
serine, lysine and histidine, found in proteins and thus form covalent bonds. These observations 
allow us to hypothesise that the NLRP3 inflammasome might be a sensible target for the design of 
targeted covalent inhibitors. 
The design of covalent inhibitors has recently gained renewed interest following the approval of 
kinase inhibitors, including afatinib, ibrutinib and many other marketed drugs [91-93].  
The binding kinetics of covalent inhibitors are different to those of traditional non-covalent drugs 
(Figure 5). While non-covalent inhibitor efficacy and potency correlates with their affinity for the 
target (ki), the efficacy and potency of covalent inhibitors mainly depends on their residence time 
(tr), namely the time the drug remains bound to its target. Covalent inhibitors are generally 
classified into two broad categories, according to whether their adducts with the protein targets are 
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functionally reversible on a biological time scale. Covalent reversible inhibitors covalently bind to 
their target protein and subsequently dissociate from it at a rate that is faster than the turnover rate 
of the protein. On the other hand, covalent irreversible inhibitors form adducts to their protein 
targets that either do not dissociate from the protein during its lifetime or do so with a kinetic half-
life that is significantly longer than the resynthesis rate of the protein. Covalent irreversible 
inhibitors often contain hard electrophilic moieties, such as epoxides, aziridines and α-haloketones, 
in their molecular structure, but most commonly employ Michael acceptors as the electrophilic 
warhead responsible for the binding to the desired target.  
 
 
 
Figure 5. The different binding modes of an inhibitor (I) to a protein target (T). A) One-step 
reversible inhibition; B) induced-fit or covalent reversible inhibition; C) covalent irreversible 
inhibition. 
 
 
Covalent inhibitors offer several advantages over non-covalent inhibitors: (i) high biochemical 
efficiency, which often translates into lower doses and reduced possibility of off-target effects; (ii) 
non-equilibrium binding, thus overcoming competition from endogenous ligands; (iii) reduced 
resistance, due to possibly conserved covalent binding to mutated sites; (iv) the uncoupling of 
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pharmacokinetics/pharmacodynamics and a prolonged duration of action that can result in less-
frequent dosing; (v) the ability to address shallow binding sites. Of course, there are also some 
potential risks involved in developing covalent inhibitors: (i) potential idiosyncratic reactions; (ii) 
excessive reactivity can lead to drug-induced toxicity; (iii) there are few advantages for proteins that 
are rapidly turned over; (iv) non-suitability for the target requiring transient inhibition. 
The full NLRP3 protein is made of 1036 aa (118.2 kDa) and contains 45 cysteine residues (Figure 
2) [94]. NLRP3’s 3D structure has not yet been elucidated. However, its close homology with 
APAF1 and NLRC4 has allowed a homology model of its ATP-binding site to be generated [95]. 
Apart from the roles of Cys8 and Cys108 in the PYD domain, which appear to be involved in 
disulphide bond formation upon NLRP3 activation [77], little is known about the role of other 43 
Cys residues. Interestingly some cysteines are located in close proximity to the putative ATP-
binding pocket [71]. Collectively, these observations have prompted medicinal chemists and 
biologists to work on covalent NLRP3inhibitors, which may be able to bind to nucleophilic cysteine 
residues and exert either the reversible or irreversible inhibition of NLRP3 conformational changes 
and subsequent activation. The structural properties of the electrophilic warheads help to regulate 
reactivity and the strength and stability of the covalent bond formed, thereby regulating the 
residence time of the inhibitor and the reversibility or irreversibility of the action. 
In this review, we describe the chemistry and biological action of NLRP3 inhibitors, that either 
have been demonstrated to covalently/irreversibly bind to NLRP3 or whose covalent behaviour has 
not yet been demonstrated, but can be inferred from chemical structure, reactivity and biological 
activity. 
 
5. (E)-3-(4-Methylphenylsulfonyl)-2-propenenitrile (BAY 11-7082) 
BAY 11-7082 (Figures 4, 6a), is a vinyl sulfone that was first synthesised in 1968 [96]. Initially, 
BAY 11-7082 was thought to inhibit the signal-induced nuclear translocation of NF-κB by 
inhibiting IKK activity and the phosphorylation of IκB in response to the signal [97,98]. It was later 
20 
 
shown to display its anti-inflammatory action through interactions with multiple targets [99,100], 
including a series of protein tyrosine phosphatases (PTPs) that act upstream of IKK and are 
involved in the phosphorylation of the IκB (inhibitor of kappa B) kinase to its active form. BAY 11-
7082’s mechanism of action relies on its ability to covalently and irreversibly bind to the conserved 
nucleophilic Cys215 present in the active sites of various PTPs, as has been demonstrated for 
PTPB1 [101]. In 2010, Juliana et al. demonstrated that BAY 11-7082 was able to directly target the 
NLRP3 inflammasome and inhibit the production of the pro-inflammatory cytokines, IL-1β and IL-
18, in a NF-κB-independent manner in macrophages [88]. The authors compared the effects of 
BAY 11-7082 to those of parthenolide, to those of a series of structurally related vinylsulfones 
(BAY 11-7085, IMPSPN, CPSMB, ESMB, PV-sulfone), and to those of one sulfonylpropanenitrile 
(MBSPN) and one sulfide (PV-sulfide) that are derivatives deprived of Michael acceptor ability 
(Figure 6a).  
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Figure 6. a) Structures of BAY 11-7082 and related derivatives used for the identification of the 
pharmacophore. b) Postulated BAY 11-7082 mechanism of reaction with nucleophile (X)-
containing proteins. The Michael acceptor domain is highlighted in red. 
 
 
This study demonstrated that, while parthenolide is a non-selective inhibitor, BAY 11-7082 was 
able to inhibit NLRP3 inflammasome, while displaying no (or only partial) inhibition of the NLRP1 
and NLRC4 inflammasomes. Experiments conducted in NG5 cells, a stable Nlrp3-/- bone marrow 
macrophage cell line that constitutively expresses NLRP3 under the control of a murine stem cell 
virus promoter, established that BAY 11-7082 was able to inhibit ATP-, nigericin- and sodium 
monourate (MSU)-induced caspase-1 activation. In NG5 cells, BAY 11-7082 also inhibited ASC-
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pyroptosome (a large ASC oligomer) formation after ATP challenge. Unlike parthenolide, BAY 11-
7082 did not show the ability to directly block caspase-1 activity in THP-1 cell lysates. The direct 
inhibition of NLRP3 ATPase activity was demonstrated using autoradiography experiments that 
were performed by incubating purified NLRP3 with [α-32P]ATP and monitoring its hydrolysis to 
[α-32P]ADP. In this experiment, BAY 11-7082 was able to decrease the NLRP3-dependent 
hydrolysis of ATP in a dose-dependent manner (5-20 µM). As expected, the activity of BAY 11-
7082 was abolished by the pre-incubation of NG5 cells with thiol-containing nucleophiles, such as 
glutathione (GSH) and L-Cys, before treatment with the activation stimulus. This observation is 
consistent with the postulated alkylation of at least one relevant (functional or regulatory) cysteine 
residue in the target protein. Finally, BAY 11-7082 was able to dose-dependently (1-20 µM) inhibit 
ATP-induced lactate dehydrogenase (LDH) release, which is used as a marker of NLRP3-dependent 
pyroptotic cell death. Structure-activity relationships (SAR) demonstrated that the presence of the 
conjugated vinyl group is essential for the activity of BAY 11-7082 and related vinylsulfones, as 
proven by the absence of activity shown by poor electrophiles, such as MBSPN and PV-sulfide 
(Figure 6a).  
The authors suggested that the postulated nucleophilic attack should occur at the more highly 
reactive position 2 (α to the nitrile moiety). However, an attack at the position 3 cannot be 
completely ruled out (Figure 6b). The essential pharmacophore was identified as being the vinyl 
sulfonyl substructure. The reactivity of BAY 11-7082 in pseudo-physiological conditions was 
measured in comparison to that of parthenolide, MNS, dimethylfumarate and ethyl 2-((2-
chlorophenyl)(hydroxy)methylacrylate (INF4E), an electrophilic acrylate derivative; the second 
order rate constant was determined using the cysteamine chemoassay. BAY 11-7082 was the most 
reactive compound in these experiments (its kinetics was too fast to be accurately determined), 
followed by parthenolide (k2 = 47.9 ± 2.9 M
−1 s−1), dimethylfumarate (k2 = 39.01 ± 0.56 M
−1 s−1), 
MNS (k2 = 2.50 ± 0.12 M
−1 s−1), and INF4E (k2 = 0.866 ± 0.006 M
−1 s−1) [102,103]. BAY 11-7082 
was found to inhibit both LPS/ATP- and LPS/nigericin-triggered IL-1β release from bone-marrow 
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derived macrophages (BMDMs) in a dose dependent manner, completely abolishing the latter at 
100 µM [102]. 
BAY 11-7082 has recently been tested at 3 mg/kg (i.p. administration) in an in vivo mice model of 
diabesity (inflammation, obesity and insulin resistance) that was generated using a high fat, high 
fructose diet [104]. The test compound was able to attenuate the diet-induced increase in NLRP3 
expression in the liver and kidneys thanks to its ability to partially inhibit NF-κB signalling. BAY 
11-7082 was also able to reduce inflammatory mediators, such as IL-1β, IL-18, and TNF, on both 
the systemic (plasma) and local (liver and kidneys) levels. BAY 11-7082 normalized the diet-
induced alteration of metabolic parameters and improved the signalling of insulin by restoring the 
IRS-1 (insulin receptor substrate 1)/Akt (serine/threonine kinase)/GSK-3β (glycogen synthase 
kinase 3 beta) pathway, which is dampened by NLRP3 activation. Finally, its chronic 
administration limited the diet-induced inflammatory damage to the kidneys and liver on both the 
morphological and functional levels. 
 
6.  3,4-methylenedioxy-β-nitrostyrene (MNS) 
MNS (Figures 4, 7a) is a synthetic nitrostyrene derivative, which was originally identified as a Src 
(proto-oncogene tyrosine-protein kinase) and Syk (Spleen tyrosine kinase) inhibitor that acted at 
low micromolar concentrations (1-3 µM). MNS was characterized for its antiaggregant properties in 
human platelets and for its ability to irreversibly inhibit p97-containing protein activity [105-107]. 
In 2014, the screening of 160 kinase inhibitors for their ability to block IL-1β release from LPS-
primed/ATP-stimulated BMDMs identified MNS as a NLRP3 inhibitor [90]. MNS was able to 
dose-dependently (0.5 – 10 µM) reduce IL-1β release in this system. IL-1β production was totally 
blocked at 10 µM, while no effect on TNF release was observed. The same results were obtained 
when the NLRP3 assembly was activated with P2X7 sparing stimuli, such as nigericin and silica. 
MNS did not have any observable effect on NLRP3, ASC or caspase-1 protein levels, which 
highlights its lack of action on the NF-κB signalling pathway. In accordance with these results, 
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MNS proved that it could significantly inhibit LPS/ATP- and LPS/nigericn-induced pyroptotic cell 
death in BMDMs at 5 µM, while it was inactive when cell death was mediated by the activation of 
NLRC4 or AIM2 inflammasomes, thus displaying its specificity of action against NLRP3. Its 
activity was largely independent of Syk kinase inhibition, as demonstrated by its ability to work 
with Syk-/- macrophages, and was not mediated by interference with K+ intracellular levels or by 
direct interaction with caspase-1. Mechanism of action studies suggested that MNS acts directly at 
NLRP3. MNS dose-dependently inhibited the ATPase activity in recombinant NLRP3 and 
prevented ASC speck formation in cells. As in the case of BAY 11-7082, a SAR study was 
conducted using a series of synthetic MNS analogues (Figure 7a). The electrophilic properties of 
the nitrovinyl moiety were identified as being essential to the biological inhibition of NLRP3 by 
this study. In the original work, its ability to react with thiols was inferred by it having a reduced 
effect in the presence of L-Cys. In a later work, using the cysteamine chemoassay it was observed 
to have marked electrophilic character, with a k2 = 2.50 ± 0.12 M
−1 s−1 [102]. Moreover, a 
biotinylated MNS analogue (Biotin-HMNS, Figure 7a), which shared the same ability to inhibit 
NLRP3, established the direct irreversible binding of MNS to the NOD and LRR domains of 
NLRP3. Collectively, these studies indicate that the covalent irreversible binding of MNS with 
cysteine residue(s) (Figure 7b) in the LRR or NACHT domain, which dampens the NLRP3 ATPase 
activity necessary for protein conformational changes, could be at the basis of its mechanism of 
action. 
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Figure 7. a) MNS and derivatives used for pharmacophore identification and in cell 
immunoblotting studies. b) putative mechanism of nucleophile trapping by MNS. 
 
 
7. Ethyl 2-(2-Chlorobenzyl)acrylate (INF39) and other acrylic acid derivatives (INF 
compounds) 
It was observed that compounds containing α,β-unsaturated carbonyl or cyano groups, such as 
parthenolide, bromoxone, and BAY 11-7082 (Figure 4), were able to directly inhibit the NLRP3 
inflammasome, which drove scientists to study the use of electrophilic warheads in the de novo 
design of covalent NLRP3 inhibitors [103]. Cocco et al. have designed a library of differently 
modulated electrophilic α,β-unsaturated derivatives (Figure 8) and screened their activity in PMA-
differentiated THP-1 cells to determine their ability to inhibit NLRP3-dependent pyroptotic cell 
death [103]. Since electrophilic compounds can also trigger undesired cytotoxicity, the cytotoxic 
properties of the synthesised compounds were checked in human renal epithelial (HK-2) cells. The 
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authors identified eleven compounds that were able to prevent > 60 % of LPS/ATP-triggered 
pyroptosis at 10 µM in human macrophages; as expected compounds 13 and 43 (Figure 8a), 
deprived of the Michael acceptor moiety, were inactive. In particular, INF4E (compound 9 in the 
cited study) was able to hamper pyroptosis by 75 % at 10 µM and was endowed with an acceptable 
TC50 of 67 µM. The acrylate derivatives were found to be generally less cytotoxic than the 
corresponding acrylonitriles in this work. Further studies, performed using INF4E, confirmed its 
ability to act as a Michael acceptor and react with GSH to generate a covalent irreversible bond, as 
demonstrated by NMR studies [103]. As is expected for a covalent irreversible drug, the 
antipyroptotic effect of INF4E (and of related compounds) was dependent on the pre-incubation 
time, and reached a plateau after 60 min of cell exposure to the compound prior to the NLRP3-
activating stimulus. Dose-dependent reductions of both ATP- and nigericin-induced pyroptosis 
were obtained, at this pre-incubation time, with EC50 values of 0.12 µM and 0.16 µM, respectively. 
A positive correlation was demonstrated to exist between reactivity with cysteamine, measured as a 
second order rate-constant (k2), and antipyroptotic activity within this series of compounds. INF4E 
inhibited ATPase activity in recombinant human NLRP3 (rhNLRP3) and showed only partial direct 
and irreversible caspase-1 inhibition (ki = 9.6 ± 3.3 μM; kinact = 3.2 ± 1.1 s-1) [102,103]. INF4E was 
tested in an ex vivo model of cardiac ischemia/reperfusion injury in which the formation of a 
NLRP3 complex was observed [108]. In this model, INF4E attenuated the formation of the NLRP3 
complex in a time-dependent manner, and displayed a significant reduction in infarct size and LDH 
release together with an improvement in post-ischemic left ventricular pressure. Moreover, the 
hearts of the INF4E-pretreated animals displayed a marked improvement in pro-survival RISK 
(Reperfusion Injury Salvage Kinase) pathway together with an improvement in mitochondrial 
function. 
The tuning of the reactivity of this series of compounds was performed in an attempt to decrease 
their cytotoxicity. A series of electrophilic compounds, generated via the chemical modulation of 
hit compound, INF4E, was designed and synthesised [102]. Their reactivity was efficiently 
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modulated and a set of less reactive non-cytotoxic compounds was obtained. The synthesised 
compounds were screened for their antipyroptotic activity and cytotoxicity in THP-1 cells, as well 
as for their ability to inhibit the ATPase activity of isolated rhNLRP3. This screening process 
suggested that INF39 (compound 11 in the cited study) was a good NLRP3 inhibitor that was 
devoid of cytotoxic properties and could irreversibly bind to NLRP3. A BRET assay, performed in 
HEK293 cells that expressed NLRP3 fused to luciferase and yellow fluorescent protein (YFP), 
revealed that INF39 affects the conformational changes of the target protein that are necessary for 
NLRP3 activation, independently of K+ efflux. Furthermore, INF39 was able to reduce IL-1β 
release in both LPS/ATP- and LPS/nigericin-stimulated BMDMs and to partially inhibit NF-κB 
signaling with no direct effect on caspase-1. 
Owing to its reduced reactivity, INF39 was stable in human serum and no detectable binding to 
human serum albumin (HSA) was observed, unlike its parent INF4E. In vitro and ex vivo ADME 
experiments were performed to assess INF39 stability in gastric and intestinal fluids, as well as its 
ability to be absorbed through the intestinal epithelium. INF39 was stable in the simulated gastric 
and intestinal fluids, however, it was rapidly metabolized in cells and converted into its active acid 
metabolite (compound 12, Figure 8). Consequently, INF39 was selected for in vivo studies in a rat 
model of experimental colitis (resembling human Crohn’s disease) and the oral route was chosen 
for in vivo experiments. The administration of INF39 in DNBS-treated rats reduced both local and 
systemic inflammatory markers, such as IL-1β, TNF and tissue myeloperoxidase (MPO), as well as 
spleen weight. The dose-dependent prevention of colon damage was observed upon morphological 
and anatomical examination. Overall, INF39 (50 mg/kg) exerted a protective effect that is similar to 
that shown by the reference drug dexamethasone (1 mg/kg), with no significant lowering of body 
weight, which is one of the side-effects correlated to chronic administration of steroidal anti-
inflammatory drugs.
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Figure 8. De novo design of NLRP3 inhibitors that are based on the acrylic acid scaffold. a) Library 
of designed electrophilic warheads. Structures of compounds selected from each series are reported. 
b) Mechanism of reaction of INF4E with glutathione (GSH).  
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The optimisation of NLRP3-directed electrophilic compounds was also attempted and acrylamide 
derivatives, which are less reactive than the corresponding acrylates, were used [95, 103]. In this 
work [95], a series of acrylamides were designed, their reactivity was fine-tuned and selectivity 
toward NLRP3 was conferred (Figure 8a, 9). Indeed, the acrylamides were found to be less reactive 
than the corresponding acrylates and no detectable binding to HSA was observed. Compounds 10 
(Figure 9) and INF58 (compound 14 in the cited study) were able to prevent NLRP3-dependent 
pyroptosis with IC50 values (1 h preincubation) of 12.7 and 23.2 µM, respectively, despite being 
less reactive than INF4E. Both compounds were able to inhibit the ATPase activity of rhNLRP3 
and decrease IL-1β release in iBMDMs, primary BMDMs and primary peritoneal mouse 
macrophages with no effect on TNF release. Interestingly, a molecular hybrid, which was formed 
by joining the acrylamide function to the glyburide substructure, was found to be inactive in this 
study (compound 15, Figure 9). Moreover, these acrylamide derivatives also significantly inhibited 
IL-1β release in macrophages that bear typical mutations (R258W, A350V, L351P), as detected in 
the CAPS pathology. A homology model of the NLRP3 NACHT domain, which contains the ATP-
binding region, was obtained using the resolved structure of NLRC4 (PDB ID: 4KXF), and a 
putative binding mode for INF58 was proposed (Figure 9) [95]. According to this hypothesis, 
Cys419 is thought to be the nucleophilic residue that is nearest to the molecule bound in the ATP-
binding pocket, thus allowing it to approach and covalently bind to the terminal position of the 
double bond in the acrylamide pharmacophore. 
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Figure 9. a) Structures of acrylamide derivatives 10, 15 and INF58. b) Putative interactions for 
INF58 in the ATP binding pocket. 
 
 
8. 5-Acetyl-6-amino-2,2-diphenyl-4-(trichloromethyl)-2,3-dihydro-1,3,2-oxazaborinin-1-
ium-2-uide (NBC6) and related cyclic diaryl boron derivatives 
The observation that the Ca2+ homeostasis inhibitor, 2-aminoethoxy diphenylborinate (2APB; 
Figure 10), was also able to inhibit the NLRP3 inflammasome [69,109] drove Baldwin et al. to 
develop new boron-based selective NLRP3 inhibitors [110]. After validating the effect of 2APB in 
LPS-primed peritoneal macrophages, which had been stimulated with different NLRP3-activating 
agents (nigericin, ATP, MSU, calcium pyrophosphate dehydrate, sphingosine and aluminium 
hydroxide), a carefully chosen series of diphenyl-substituted compounds (Figure 10), which are 
structurally similar to 2APB, was tested in order to discover the molecular determinants for the 
inhibition of NLRP3 inflammasome by 2APB. 
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Figure 10. Representative compounds used for 2APB pharmacophore identification.  
 
 
The authors successfully identified that a boron atom linked to an oxygen atom was the minimal 
pharmacophore necessary for the inhibition of NLRP3-dependent IL-1β release in cells. The 
synthesis of a series of boron-containing compounds identified two potent hit compounds, BC7 and 
BC23 (Figure 11), which both bear a diphenyl substituted oxazaborine ring. These compounds 
displayed IL-1β inhibition with IC50 values of 1.2 and 2.3 µM, respectively in LPS/ATP-stimulated 
BMDMs. Three series of differently substituted oxazaborines, dioxaborines, and diazaborines 
(Figure 11a) were further synthesised and screened, which led to the identification of oxazaborine 
derivative NBC6 as the most promising compound of those investigated. NBC6 inhibited NLRP3-
dependent IL-1β release (IC50 = 0.574 µM in LPS/nigericin-treated THP-1) with an action that was 
not dependent on either intracellular [Ca2+] or direct caspase-1 inhibition. SAR were also 
determined for the borine-derived scaffold, leading to the finding that the electron-withdrawing and 
lipophilic trichloromethyl substituent at position 4 of the ring played a fundamental role. 
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Importantly, X-ray studies displayed the electrophilic character of the boron atom present in the 
oxazaborine derivatives [110,111]. The electrophilic character of these compounds is further 
supported by the hydrolysis of BC23 observed in DMSO/D2O solution at 37 °C; in this condition 
BC23 displays a half-time of approximately 24 h (Figure 11b) [111]. It is worth noting that NBC6 
was able to block both canonical and non-canonical NLRP3 activation, was selective with respect to 
NLRC4 and absent in melanoma 2 (AIM2) inflammasomes and was devoid of cytotoxic properties 
in HEK293 and HepG2 cells. In terms of mechanism, NBC6 was able to prevent ASC-speck 
formation, which is a marker of inflammasome assembly, and irreversibly block NLRP3-dependent 
IL-1β release form iBMDMs, which is similar to behaviour shown by the nitrostyrene derivative, 
MNS, that was used as the reference compound in the study. NBC6 also inhibited IL-1β release 
from neutrophils at 10 µM. 
NBC13 (Figure 11a), an analogue of NBC6 that shares the same in vitro potency (95 % IL-1β 
release inhibition at 10 µM in LPS/nigericin-stimulated THP-1), has been selected for in vivo 
studies in a model of LPS-driven peritonitis. NBC13, administered by oral gavage at a dose of 50 
mg/kg, was able to decrease IL-1β levels in peritoneal lavage fluid and those of both IL-1β and IL-
1α in plasma, similarly to the reference compound MCC950. These data suggest that cyclic 
diarylboron derivatives show promise in their future development as potential drugs for irreversible 
NLRP3 inhibition [112].  
 
 
33 
 
 
 
Figure 11. a) Development of oxazaborines, dioxaborines, and diazaborines from hit compounds 
BC7 and BC23; b) nucleophilic attack of water to the boron atom of BC23. 
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9. (Z)-4-((4-Oxo-2-thioxo-3-(3-(trifluoromethyl)benzyl)thiazolidin-5-ylidene)methyl)benzoic 
acid (CY-09) 
In 2017, Jiang et al. reported on the discovery of a class of thiazolidinone derivatives that act as 
potent NLRP3 inhibitors [113]. The first member of this class, namely C172 (Figure 12a), was 
identified via a screening of a library of cystic fibrosis transmembrane conductance regulator 
(CFTR) channel inhibitors. The screening, conducted in LPS/nigericin-stimulated BMDMs, 
revealed that C172 was able to dose-dependently (0.5 – 20 µM) reduce caspase-1-mediated IL-1β 
release with no detectable effect on LPS-priming. Its ability to inhibit CFTR was not responsible for 
its NLRP3 inhibition, as demonstrated in work with cftr-/- BMDMs. The authors later tested a series 
of previously synthesised C172 derivatives [114]. A compound named CY-09 (Figure 12) emerged 
from this screening as a potent NLRP3 inhibitor with negligible activity on CFTR [113].  
CY-09 exhibited a dose-dependent (1–10 μM) inhibitory effect on MSU-, nigericin- and ATP-
induced caspase-1 activation, and IL-1β secretion in LPS-primed BMDMs. Moreover, CY-09 
inhibited non-canonical NLRP3 activation as driven by the administration of intracellular LPS. All 
these effects were independent of LPS-induced priming and NF-κB activation, as demonstrated by a 
lack of activity on TNF secretion and on the expression of pro-IL-1β and NLRP3. In keeping with 
these results, CY-09 was also able to prevent the NLRP3-dependent pyroptosis of BMDMs that 
were treated with LPS/nigericin by approximately 80 % at 10 µM. CY-09 was found to be as potent 
as BAY 11-7082, parthenolide and sulforaphane, while being less effective than MCC950 in 
inhibiting IL-1β release from LPS/nigericin-stimulated BMDMs. Its NLRP3 selectivity over 
NLRC4 and AIM2 inflammasomes was also demonstrated. 
 
35 
 
 
 
Figure 12. a) Structure of hit compound C172, lead compound CY-09 and its biotinylated 
analogue. b) Possible point of attack by protein nucleophiles on CY-09. 
 
 
The mechanism of action of CY-09 was also investigated. Treating PMA-differentiated THP-1 cells 
with a biotinylated analogue (Biotin-CY-09; Figure 12a) demonstrated that CY-09 binds directly to 
the NACHT domain of NLRP3 with an equilibrium dissociation constant (kD) of 0.500 µM, as 
measured in thermophoresis experiments. The binding of CY-09 appears to occur at the Walker A 
motif level and results in the dose-dependent inhibition of NLRP3 ATPase activity, with a maximal 
85 % inhibition at 1 µM. This inhibition is highly specific for NLRP3 ATPase with regards to 
NLRC4, NLRP1, NOD2 and retinoic acid-inducible gene I (RIG-I), as proven by work with 
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purified proteins. In summary, the authors proved that CY-09 was able to bind to NLRP3, inhibiting 
its ATPase activity and consequently dampening NLRP3 oligomerisation, NLRP3-ASC recruitment 
and inflammasome assembly. No effects on potassium efflux, chloride efflux, mitochondrial 
damage or mitochondrial ROS production were detected. 
CY-09 reduced nigericin-triggered caspase-1 activation and IL-1β secretion both in human 
macrophages and in peripheral blood mononuclear cells (PBMCs) in a dose-dependent manner (1-
10 µM). The treatment of synovial fluid cells (SFCs), which had been obtained from patients 
diagnosed with acute and chronic gout, with CY-09 (5 and 10 µM) led to a remarkable reduction in 
activated caspase-1 and IL-1β levels, while having no effect on TNF. 
A preliminary in vitro pharmacokinetic profile showed that CY-09 has a half-life of 145 min in 
human and liver microsomes, while it demonstrated no relevant inhibition of CYP1A2, CYP2C9, 
CYP2C19, CYP2D6 or CYP3A4. Furthermore, no effects on the human ether-a-go-go (hERG) 
channel were observed up to 10 µM. After a single oral dose (10 mg/kg) of CY-09, a maximal 
concentration (Cmax) of 3.25 ng/mL was detected in the plasma of C57BL/6j mice after 30 min 
(tmax). Bioavailability was 72 %, half-life (t½) 5.1 h, and the mean residence time MRT(0-∞) was 2.4 
h.  
In vivo studies showed that CY-09 displays promising activity in mice bearing the Nlrp3 (A350V 
neoR) mutation, which is associated to human MWS-syndrome. In this model, the oral 
administration of 40 mg/kg CY-09 significantly prolonged the survival time of mutant mice, 
suggesting that the lethal inflammation caused by the NLRP3 gain of function mutation was 
suppressed. 
CY-09 was tested in high-fat diet- (HFD) fed mice, which are a model of Type 2 Diabetes (T2D). In 
this model, the intraperitoneal administration of CY-09 (2.5 mg/kg QD) for six weeks produced 
beneficial effects for body weight, insulin sensitivity and blood glucose levels in HFD-WT mice, as 
compared to HFD-Nlrp3-/- mice, thus underlining the NLRP3-dependent action in vivo. 
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Metaflammation [115] and hyperglicaemia also decreased in HFD-treated mice. Furthermore, CY-
09 had no adverse effects in untreated mice that had been fed a standard diet.  
Interestingly, the authors did not check for the reversibility of NLRP3 inhibition, in either the 
isolated protein or in cells, in this work. However, our experience working with covalent inhibitors 
leads us to believe that, given the electrophilic moiety present in CY-09, the methylene group at the 
5 position of the thiazolidinone ring would most likely behave as an electrophile (Figure 12b) and 
irreversibly/reversibly trap the nucleophilic residues present in the proximity of Walker A motif of 
the NACHT domain in NLRP3. This behaviour can be also inferred from CY-09’s prolonged action 
in the MWS-mutant mice model, which lasted for a few days (5-23 days) after drug withdrawal. 
However, the reversibility of this binding in a cellular environment is still to be confirmed. The vast 
amount of in vivo data justifies the development of CY-09 into an effective small molecule NLRP3 
inhibitor. 
 
10. Dimethyl fumarate (DiMF) and monomethyl fumarate (MMF) 
The first therapeutic use of dimethylfumarate dates back to 1959 when W. Schweckendiek treated 
himself with a mixture of fumaric acid esters (FAEs) in an attempt to relive the symptoms of 
psoriasis [116]. The treatment was somewhat successful and, although the FAEs mechanism of 
action was not clear, several clinical trials demonstrated the effectiveness and safety of oral 
treatment with FAEs [117,118]. In 1994, Fumaderm®, a drug product that consists of dimethyl 
fumarate, calcium-, magnesium- and zinc-salts of monoethyl fumarate was approved in Germany as 
an oral treatment for psoriasis vulgaris. Later clinical research demonstrated that dimethyl fumarate 
(DiMF; Figure 13a), also labelled as BG-12 in clinical studies, showed beneficial therapeutic effects 
in patients affected with relapsing-remitting multiple sclerosis (RRMS) [119-121]. Finally, 
Tecfidera®, a drug product containing DiMF, was approved for the treatment of RRMS in 2013. 
Although vast amounts of in vivo data are available, the DiMF mechanism of action is still not fully 
understood.  
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It is important to note that, after oral administration, DiMF is readily hydrolysed, either 
spontaneously or by esterases, to its metabolite monomethylfumarate (MMF; Figure 13a). No 
detectable amount of DiMF is present in the portal vein or in plasma, while MMF and the GSH-
conjugated derivative (S)-(1,2-dimethoxycarbonylethyl)gluthathione (GS-DMS) are readily formed 
and can be detected both ex vivo and in vivo [122,123]. Both DiMF and MMF are reactive Michael 
acceptor molecules and can react with biological nucleophiles (Figure 13b), such as the Cys 
residues of proteins and GSH, but DiMF shows the greater reactivity due to its neutral nature at pH 
7.4, while MMF is monoanionic at the same pH [102, 124]. 
 
 
 
Figure 13. a) Molecular structure of dimethylfumarate (DiMF) and its metabolite 
monomethylfumarate (MMF); b) Reaction pathways of DiMF and MMF with biological thiols. 
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In 2015, Miglio et al. tested the ability of DiMF and its monomethyl metabolite MMF to inhibit 
NLRP3-mediated pyroptosis in differentiated THP-1 cells that had been stimulated with LPS/ATP. 
Both of these compounds were able to irreversibly inhibit pyroptotic cell death and their effects 
were time- and dose-dependent. Interestingly, both the potency and the efficacy of tested FAEs 
were related to their reactivity and cell permeability, with DiMF (pIC50 = 6.6) being more potent 
than MMF [125]. 
DiMF and MMF inhibited IL-1β release and caspase-1 activation in LPS/ATP-treated human 
macrophages and had no significant direct effect on caspase-1 activity or pro-IL-1β expression. 
This effect was concentration-dependent, in the 0.01 – 10 µM range, with a determined pIC50 of 5.8 
for DiMF and 6.8 for parthenolide, which was used as the reference comparator in this study. MMF, 
the most abundant in vivo metabolite of DiMF, failed to reach 50 % inhibition, even at 10 µM 
concentration, in both pyroptosis and IL-1β release experiments. Finally, DiMF did not inhibit 
NLRP3 ATPase activity in rhNLRP3 [102]. In vitro inhibition of NLRP3 activation, triggered with 
different stimuli (LPS/ATP, LPS/cholesterol and LPS/alum), was recently confirmed for both DiMF 
and MMF in THP-1 cells, together with their ability to dose-dependently inhibit the formation of 
intracellular ASC-specks [126]. Until now, no data about the specificity of DiMF or MMF toward 
NLRP3 inflammasome have been reported. 
Recent evidence suggests that MMF may also act via a complex and multitarget mechanism, 
involving agonism of the hydroxycarboxylic acid 2 (HCA2) receptor and the activation of the 
Nuclear Factor (erythroid-Derived 2)-Like-2 (Nrf2) pathway via the alkylation of Kelch-like ECH-
associated protein 1 (Keap1), which is a physiological effect triggered by several electrophilic 
molecules [127]. The crosstalk between Nrf2-triggered pathways and NLRP3 signalling is rather 
complex; as a matter of fact, anti-inflammatory and immunomodulatory effects for DiMF were 
evidenced in both WT and Nrf2-/- autoimmune encephalomyelitis (EAE) mouse models [128]. 
These effects are likely to be mediated by NLRP3 inhibition. Moreover, a recent paper [129] 
demonstrated that Nrf2-induced gene expression is not involved in inflammasome regulation, while 
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DiMF acts directly on NLRP3 to dampen inflammasome-dependent inflammation in vivo. These 
two pathways are inversely correlated in cells, where NLRP3 activation downregulates Nrf2 
expression. The characterization of electrophilic NLRP3 inhibitors is complicated by the fact that 
most of the electrophilic compounds are able to interact with Keap1, thereby activating the Nrf2-
mediated responses. When working in cells, these two effects can be discriminated by using 
different experiment times: the NLRP3-mediated pyroptotic cell death is rapidly (< 1 h) triggered 
by common NLRP3 activating stimuli and inhibited by electrophilic NLRP3 inhibitors, while Nrf2-
mediated gene expression usually requires longer times (> 3 h) to be detected [103]. 
 
11. N-(3’,4’-dimethoxycinnamoyl)-anthranilic acid (Tranilast) 
Tranilast (TR; Figure 14a) is an approved drug that is clinically used for the therapy of asthma and 
other inflammatory diseases in South Korea and Japan. TR is generally well tolerated in patients. 
However, much like DiMF, its mechanism of action is still poorly understood [130]. Huang et al. 
have recently discovered that TR was able to prevent NLRP3-activation in LPS/nigericin-treated 
BMDMs by inhibiting inflammasome assembly [131]. TR binds to the NACHT domain of NLRP3 
both in cells and in the isolated protein, as demonstrated in pull down experiments conducted with a 
biotinylated analogue (undisclosed structure). TR proved to be selective for NLRP3 as it was unable 
to bind to NLRP1, NLRC4, NOD1 and NOD2 in HEK293 cells that overexpress these proteins. 
This direct effect on inflammasome assembly results in the inhibition of caspase-1 activation and 
IL-1β secretion both in BMDMs and in human macrophages. These effects were dose-dependent 
(25 – 100 µM) with a maximal inhibition of approximately 90 % at 100 µM. Interestingly, TR was 
able to block the NLRP3-dependent IL-1β release triggered by a variety of NLRP3-activating 
stimuli, such as ATP, MSU, Alum and cytosolic LPS (cLPS). No effects on either NLRP3 and pro-
IL-1β expression, or on IL-6 and TNF production were observed when TR was administered 3 h 
after the LPS stimulation of BMDMs. However, a decrease in pro-IL-1β expression and IL-6 
production was found when TR was administered 30 min before LPS challenge, thus suggesting 
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that possible interference with NF-κB pathway is present. Effects on NLRP3 expression and TNF 
production were negligible in the same model. Experiments using cLPS demonstrated that, while 
TR was able to block non-canonical NLRP3 activation, it was not able to prevent cLPS-induced 
gasderminD cleavage and subsequent pyroptotic cell death in BMDMs. Finally, the activation of 
NLRC4 and AIM2 inflammasomes was not blocked, which demonstrates that NLRP3 may be a 
preferential target for TR. The presence of a direct effect on intracellular K+ concentration or on 
mitochondrial damage and ROS production was also excluded. 
 
 
 
 
Figure 14. a) Molecular structure of tranilast (TR) electrophilic functionality is written in red; b) 
possible pathway for covalent interaction with protein target.  
 
 
Co-immunoprecipitation studies clarified that TR acts by directly binding to NLRP3 and thus 
prevents NLRP3-NLRP3 and NLRP3-ASC interactions. This mode of action allows the blockade of 
NLRP3-oligomerisation and the subsequent NLRP3 assembly. Interestingly, TR does not inhibit the 
ATPase activity of NLRP3, indicating that the binding site is likely to be far away from the ATP-
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binding pocket in the NACHT domain of NLRP3. From a mechanistic point of view, it is 
predictable that TR is able to target a shallow binding site on NLRP3, as this is a typical advantage 
that can be obtained using covalent inhibitors [91]. A mechanism involving the covalent binding of 
electrophilic TR with a nucleophile exposed on the surface of the NLRP3 protein (Figure 14b), can 
therefore be hypothesised rather than a mechanism involving highly specific binding into a deep 
pocket of the target (typical of non-covalent small molecule inhibitors). This kind of binding could 
be the basis of the observed block of protein-protein interactions.  
Ex vivo experiments that worked with patient-derived SFCs also demonstrated that TR (50 and 100 
µM) is effective in reducing NLRP3-mediated IL-1β release with no detectable effect on TNF 
secretion. Overall, TR exerts a protective effect in different models of NLRP3-driven acute 
inflammation.  
TR (200 mg/kg; i.p.) efficiently suppressed IL-1β release and neutrophil recruitment when tested in 
a mouse model of peritonitis that had been evoked by MSU. In this model, its effect was 5 fold 
lower than the effect obtained after the administration of MCC950 (40 mg/kg; i.p.). After oral 
administration (200 mg/kg in CMC), TR was effective in a model of MSU-induced gouty arthritis 
and significantly reduced MSU-induced joint swelling and IL-1β levels in the joint tissue 
supernatant. At 100 mg/kg (oral administration), TR was also able to prevent body weight loss and 
prolong survival time in mice bearing the MWS-associated mutation Nlrp3 (A350VneoR). TR was 
tested in mice that were fed with a HFD that simulates the metainflammatory condition typical of 
T2D in order to ascertain its effectiveness in chronic NLRP3-driven inflammation. TR was 
administered orally at 25 and 50 mg/kg to HFD-fed mice. TR decreased weight gain, in a dose-
dependent manner, had no effect on food intake, prevented the elevation of fasting glucose 
concentration and ameliorated insulin sensitivity. Moreover, histological analyses revealed a 
marked decrease in liver steatosis in HFD mice treated with TR. It is worth noting that TR had no 
effect in control mice that were fed with a standard diet. An examination of inflammatory 
parameters associated with the NLRP3-induced metabolic disorders revealed reduced caspase-1 
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activation, and reduced production of IL-1β and TNF in the adipose tissue and liver of TR-treated 
mice. However, these in vivo effects were not significantly different in the two TR doses used in 
this study. Interestingly, the same results were obtained when the treatment with TR was initiated 
14 weeks after the start of the HFD regimen. These experiments indicate that TR can be effective in 
reducing T2D-associated metabolic disorders via the inhibition of NLRP3 inflammasome 
signalling. 
An analysis of results obtained while working with TR indicate that this drug can also act upstream 
of inflammasome signalling, as proven by its ability to prevent IL-6 release and pro-IL-1β 
expression, when administered to macrophages before LPS challenge. The in vivo effects of TR 
may be the result of multiple site targeting, rather than simple NLRP3 inflammasome inhibition. 
 
12.  (E)-(2-cyclohexylimino)-6-methyl-6,7-dihydro-5H-benzo[1,3]oxathiol-4-one (BOT-4-
one) 
Early work on benzoxathiol-one derivatives identified this class of compounds as potential anti-
psoriatic agents in the 1970s [132]. BOT-4-one (Figure 15a) is a benzoxathiole derivative 
developed from a series of anti-proliferative compounds that were originally reported on by 
Venkateswararao et al. in 2012 [133]. This compound was later investigated for its 
immunomodulatory activity in a dermatitis model [134]. BOT-4-one is an alkylating agent that 
provides the complete inhibition of IKKβ activity at a 30 µM concentration. This action is reflected 
in the downmodulation of the NF-κB signalling pathway. In silico studies have shown that it is 
predicted to alkylate Cys179 in the activation loop of IKKβ kinase [134]. 
BOT-4-one has recently been reassessed as a potential NLRP3 inhibitor thanks to the discovery of  
NLRP3 inflammasome’s sensitivity to electrophiles [135]. The authors found that BOT-4-one is 
able to dampen both canonical and non-canonical NLRP3 inflammasome activation. BOT-4-one 
dose-dependently (0.75 – 3 µM) inhibited LPS/ATP-, LPS/nigericin-, and LPS/silica-induced 
caspase-1 activation, IL-1β release and pyroptosis (inhibition was less efficient when pyroptosis 
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was triggered by silica) in both BMDMs and THP-1 cells. The almost complete inhibition of these 
effects was reached at a 3 µM concentration. 
 
 
 
Figure 16. a) Molecular structure of BOT-4-one; b) predicted reactivity with Cys179 in IKKβ 
kinase (bold arrow) and alternative positions available for nucleophilic attack (plain arrows) 
 
 
In BMDMs, BOT-4-one was observed to be somewhat more efficient than MNS and BAY 11-7082. 
BOT-4-one acts specifically against NLRP3, does not inhibit AIM2 and only partial inhibits 
NLRC4. The authors hypothesized that the effect on NLRC4 could be mediated by NLRP3-
inhibition, as NLRP3 might be recruited as a coactivator to potentiate NLRC4 activation [136]. 
However, direct action on NLRC4, by BOT-4-one, cannot be ruled out and the possibility 
necessitates further study. In order to define the site of action of BOT-4-one, the authors verified its 
possible effects on pro-IL-1β, NLRP3 and ASC expression together with its effects on α-tubulin 
acetylation and mitochondrial destabilization. None of these parameters were affected by BOT-4-
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one treatment in macrophages. This compound was, however, able to attenuate the ATPase activity 
of recombinant NLRP3 (approx. 80 % reduction at 3 µM) and suppress ASC-speck formation in 
BMDMs, both in a dose-dependent manner. These effects were attributed to BOT-4-one’s ability to 
alkylate relevant nucleophilic residues in NLRP3, as demonstrated by its lack of action in the 
presence of an excess of L-cysteine. In an interesting finding, the authors highlighted the capacity 
of alkylating agent, such as BOT-4-one, MNS and BAY 11-7082, to up-regulate the ubiquitination 
of NLRP3. This effect and ATPase inhibition are independent of PKA activity, which is not 
affected by BOT-4-one or other known NLRP3 alkylating agents (MNS and BAY 11-7082). It is 
not clear whether this action is mediated through the inhibition of BRCC3 deubiquitinase (as found 
with compound G5 [53]), or through the promotion of NLRP3 ubiquitination. It is important to note 
that the alkylation of IKKβ was predicted to happen via the nucleophilic addition of Cys179 to the 
carbonyl group of BOT-4-one. However, in the case of NLRP3, a Michael addition to either 
positions 2 or 7a of BOT-4-one cannot be ruled out (Figure 15b). The anti-inflammatory action of 
BOT-4-one was validated in vivo in the described model of MSU-induced acute peritonitis in mice 
[14]. BOT-4-one (10 mg/kg, i.p.) significantly decreased IL-1β in the lavage fluid and reduced 
neutrophil infiltration in the inflammation site. Overall, BOT-4-one is another interesting covalent 
inhibitor in the arsenal of NLRP3-blocking molecules. 
 
13. (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide (WP1066) 
WP1066 (Figure 16a) is an acrylamide derivative that was originally synthesised and patented as an 
antiproliferative agent at the University of Texas [137].  
WP1066 is an inhibitor of activated Janus kinases (JAKs) and acts by blocking the phosphorylation 
of the signal transducer and activator of transcription 3 (STAT3). This mechanism of action leads to 
growth inhibition and apoptosis induction in a variety of cancer cell lines, including those of acute 
myelogenous leukemia, malignant glioma and melanoma [138-140]. Honda et al. screened a library 
of 365 compounds with differentiated THP-1 cells that were treated with LPS/imiquimod, to induce 
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pro-IL-1β expression and NLRP3 priming and activation, with the aim of discovering small 
molecules that can regulate the release of mature IL-1β from cells. In this experiment, WP1066 was 
found to decrease IL-1β secretion (1-10 µM) and provided almost complete suppression in the 2 – 
10 µM range. This compound was also validated using classical NLRP3 activators, such as 
nigericin, MSU and hypotonic medium. The same results were obtained working with peritoneal 
exudate cells (PECs). In this model, the activation of caspase-1 and the release of IL-1β were 
inhibited as well. Interestingly, authors reported that imiquimod, similarly to nigericin, was able not 
only to activate NLRP3, but also to induce differentiated THP-1 cell death, which was monitored 
using the LDH assay and propidium iodide (PI) staining. 
 
 
 
Figure 16. a) Molecular structure of WP1066 and its analogue AG490; b) predicted reactivity with 
nucleophilic residues: the reversibility of the reaction depends on the acidity of the α-hydrogen 
(highlighted in cyan). 
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In this system, WP1066 completely abolished cell death at 10 µM, while only a weak effect was 
obtained when working with the caspase-1 inhibitor Ac-YVAD-CMK. In PECs, WP1066 exerted 
the same anti-pyroptotic action as seen in THP-1. Notably, the caspase-1 inhibitor was inefficient in 
preventing imiquimod-induced cell death in this case. These results suggest that either imiquimod 
triggers a type of cell death that is different to pyroptosis, or that WP1066 exerts its action by 
targeting multiple signalling pathways rather than the NLRP3/caspase-1 pathway alone. The authors 
decided to study the influence of STAT3 signalling on inflammasome activation by monitoring the 
phosphorylation of STAT3 at Tyr705 (P-Y705) and Ser727 (P-S727) in order to identify possible 
alternative target(s) for WP1066. Interestingly, the authors noted that neither imiquimod nor the 
other NLRP3 activators used were able to promote (or further activate) the phosphorylation of 
Y705. WP1066 slightly attenuated the formation of STAT3 P-Y705 in PMA-differentiated and 
LPS-stimulated THP-1 cells. The known JAK/STAT inhibitors, ruxolitinib and AG490 (a close 
analogue of WP1066, figure 16a), failed to suppress, or only slightly affected IL-1β release or the 
pyroptotic process. Collectively, these results indicate that STAT3 signalling is not involved in the 
release of IL-1β, and that the NLRP3 and STAT3 signalling pathways are not likely to interfere 
with each other in THP-1 cells. Rather intriguingly, WP1066 (10 µM) was cytotoxic in 
undifferentiated THP-1 cells and in A172 and T98G, two glyoma cell lines; this cytotoxicity was 
not dependent on STAT3 inhibition.  
Mechanistically speaking, WP1066 is an alkylating agent, which can react with biological 
nucleophiles. Its structure contains a double electrophilic moiety, namely an acrylamide, and an 
acrylonitrile. The adduct obtained following Michael reaction with nucleophiles may be stable, 
leading to covalent irreversible inhibition, or can revert to the starting compounds, leading to 
covalent reversible inhibition [141]. The reversibility of the reaction largely depends on the acidity 
of the hydrogen α to the nitrile and the amide functionality (Figure 16b), and on the cellular 
microenvironment. Since WP1066 was able to induce JAK2 protein degradation [138], it is likely 
that WP1066 acts as an irreversible alkylating agent on JAK2 and this activity may be translated to 
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NLRP3 when it is the target. Some aspects of the mechanism of NLRP3 inhibition by WP1066, as 
well as its in vivo efficacy, still require further investigation. 
 
14. Caffeic acid phenylethyl ester (CAPE) 
Lee et al. have selected caffeic acid phenylethyl ester (CAPE; Figure 17) from a library of 
compounds of natural origin as part of their search for new molecules for the treatment of gouty 
arthritis. CAPE was tested in BMDMs and THP-1 cells that had been primed with LPS and 
stimulated with MSU crystals [142]. In this model, CAPE (0.5 – 10 µM) was able to inhibit ASC 
speck formation, caspase-1 activation and IL-1β secretion in a dose-dependent manner, albeit with 
slightly lower efficacy in human macrophages than in BMDMs. CAPE also inhibited the release of 
IL-1β in BMDMs after a challenge with classical stimuli, such as ATP and nigericin.  
 
 
 
Figure 17. Molecular structures of caffeic acid phenylethyl ester (CAPE) and its biotinylated 
analogues that were used for mechanism of action studies. 
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These results were further validated in an in vivo mouse model of acute inflammation. CAPE (30 
mg/kg) was administered orally after air pouches were generated on the backs of the mice. One 
hour later, the NLRP3 inflammasome was activated by MSU injection (3 mg/mL/mouse) into the 
air pouch. In this experimental model, CAPE decreased caspase-1 activity, IL-1β, and IL-18 
secretion in the air pouch exudates, inhibiting myeloperoxidase (MPO) activity and neutrophil 
infiltration into the site of inflammation. Similar results were observed in a gouty arthritis model 
obtained by MSU injection into the hind foot of mice. In this model, CAPE (30 mg/kg per os) was 
able to decrease caspase-1 activation, IL-1β, IL-18, MPO activity, neutrophil infiltration and foot 
pad thickness, while no TNF inhibition was detected. The authors conducted mechanism of action 
studies in 293T cells that overexpressed the inflammasome components NLRP3, ASC and caspase-
1, both alone and in combination, by measuring the ability of assembled inflammasome to activate 
the response of luciferase reporter gene (iGLuc). With this assay, the authors excluded the 
possibility of direct action on caspase-1, and identified ASC as a preferential target for CAPE. The 
production of three biotinylated analogues of CAPE, namely BT-CA (active), BT-DHC (active), 
and BT-DMC (inactive) (Figure 17) allowed the BT-CA-ASC and BT-DHC-ASC complexes to be 
isolated. Surface Plasmon Resonance (SPR) studies further confirmed CAPE’s direct binding to 
ASC. Its ability to bind ASC means that CAPE was also able to inhibit the activation of AIM2 
inflammasome, which also requires ASC for its assembly. 
This study shows that ASC is a possible target for CAPE. SPR experiments with different 
concentrations of CAPE, followed by washout, also demonstrated that in vitro binding between the 
isolated ASC protein and CAPE appears to be reversible. This was further supported by pull down 
experiments in cell lysates conducted with BT-DHC, which is the biotinylated analogue of CAPE 
that is deprived of the Michael acceptor moiety. BT-DHC was still able to interact with ASC under 
these conditions. From these results, we might conclude that the free catechol ring is fundamental 
for the interaction between CAPE and the ASC component of the inflammasome. However, while 
this study demonstrates the reversible binding of CAPE to ASC, we feel that CAPE may still 
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irreversibly interact with either NLRP3 or other proteins that are involved in the NF-κB signalling 
pathway [143].  
 
15. Other electrophilic NLRP3 inhibitors  
We have described, in the previous sections, the mode of action of the most frequently studied 
compounds and classes of compounds that act (or are likely to act) as irreversible NLRP3 inhibitors. 
While other compounds that can inhibit NLRP3 signalling have been described, they suffer from a 
lack of deep investigation into their modes of action, or they act by irreversibly inhibiting multiple 
targets beyond the NLRP3 inflammasome. In the following pages, we will briefly discuss some 
compounds that fall into the scope of this review and that are cited as NLRP3 inhibitors in recent 
literature. 
Some natural derivatives have been found to irreversibly inhibit NLRP3 signalling, and include 
parthenolide (Figure 4) [88], costunolide, helenalin [144], jolkinolide [145] and arglabin [146] 
(Figure 18). These natural derivatives all possess a γ-methylene lactone moiety that is known to 
react with a variety of nucleophiles, such as the nitrogen atom in alanine, the ring nitrogen in 
histidine, and the sulphur atom in cysteine and GSH [145]. Their high reactivity means that γ-
methylene lactone derivatives can trap cellular nucleophiles that are involved in a number of 
different signalling pathways. Consequently, it is not surprising that they exert anti-inflammatory 
effects through the inhibition of multiple targets along the NF-κB/NLRP3/caspase-1 axis [147-149]. 
None of these can be regarded as selective NLRP3 inhibitor. However, the anti-inflammatory and 
antiatherogenic activity of arglabin in APOE.Ki mice, susceptible to develop atherosclerosis under 
HFD regimen, looks particularly promising [146]. 
The flavonoid derivative Oroxylin A (Figure 18) has recently proven that it can inhibit dextran 
sulfate sodium (DSS)-induced colitis in mice via both the inhibition of the NF-κB-mediated 
expression of NLRP3 and via direct action exerted on the NLRP3 assembly [150]. 
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Figure 18. Molecular structures of representative natural derivatives that act as multi-target anti-
inflammatory agents and NLRP3 inhibitors. 
 
 
Chalcones have been widely studied because of their ability to react, in a Michael fashion, with 
cysteines in proteins and form covalent protein-chalcone adducts, thereby irreversibly blocking 
protein function [151,152]. Isoliquiritigenin (ILG), a flavonoid with a chalcone substructure that 
can be isolated from Glycyrrhiza uralensis (Figure 19), has shown interesting NLRP3 signalling 
inhibition. ILG was initially characterized as an inhibitor of TLR4 activation/NF-κB activity, and of 
mitogen-activated protein kinase (MAPK) activity. However, its ability to inhibit NLRP3 
activation, independently from TLR4 antagonism, has recently been demonstrated [153]. In 
BMDMs, ILG inhibited NLRP3 inflammasome-induced IL-1β production and caspase-1 activation 
to a higher extent than parthenolide and glyburide. Ex vivo and in vivo analyses revealed that ILG 
reduced HFD-induced IL-1β and caspase-1 production from white adipose tissue, and lowered 
weight gain, hypercholesterolemia, hepatic steatosis, adipose tissue inflammation and insulin 
resistance. Some of these effects are shared by glycyrrhizin (GL), a saponine derivative that 
contains an electrophilic function that is isolated from plants of the Glycyrrhiza genus (Figure 19). 
However, GL action is not specific against NLRP3, as GL can also inhibit AIM2 inflammasome, 
albeit at higher doses.  
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Figure 19. Molecular structures of isoliquiritigenin (ILG) and glycyrrhizin (GL). 
 
 
Another natural compound that can inhibit the NLRP3 inflammasome is sulforaphane (R-1-
isothiocyanato-4-methylsulfinylbutane) [154,155], an isothiocyanate derivative that is isolated from 
cruciferous vegetables (Figure 20a). Sulforaphane has long been known for its anti-inflammatory 
and cytoprotective effects [156]. Its anti-inflammatory effects have been ascribed to its ability to 
activate transcription factor Nrf2. Keap1 has recently been isolated and identified to be an 
inhibitory regulator of Nrf2 that binds to the N-terminal Neh2 domain of Nrf2. The cysteine-rich 
Keap1 protein (27 Cys residues) activates Nrf2 following its reaction with electrophiles to form 
covalent adducts, which stabilizes Nrf2 and results in enhanced nuclear Nrf2 levels. As a matter of 
fact, sulforaphane stabilizes and activates the Nrf2 transcription factor by reacting with the cysteine 
residues of its repressor, Keap1 [157]. Thiols react with sulforaphane via addition to the 
isothiocyanate carbon to yield S-thionoacyl adducts (Figure 20b) as demonstrated for the Keap1 
protein. The formed adduct is stable in physiological conditions and can only be cleaved in the 
presence of other nucleophiles, via a transacylation reaction or by protease-mediated hydrolysis 
[158]. Additional evidence suggests that sulforaphane may react directly with other cellular targets, 
such as TLR4 and tubulin, in a thiol-dependent manner, via the formation of covalent bonds [159-
161]. 
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Recent studies have demonstrated that sulforaphane is able to prevent the activation of multiple 
inflammasomes, namely NLRP3, NLRP1, NLRC4 [154,155]. The ability of sulforaphane to 
attenuate the activation of AIM2 inflammasome is still controversial. Its action is not dependent on 
either Nrf2 activation or ROS scavenging, and may occur through a direct covalent interaction with 
the inflammasome proteins, thus preventing conformational changes that are essential for 
inflammasome activation and assembly. Interestingly, sulforaphane proved itself to be active in an 
in vivo model of MSU-induced peritonitis as it was able to reduce IL-1β maturation following the 
i.p administration of 25 mg/kg twice in four hours [154,155].  
 
 
 
 
Figure 20. a) Molecular structure of sulforaphane. b) Reaction of sulforaphane with thiol 
containing proteins and trans-thioacylation.  
 
 
Bromoxone, together with some of its synthetic analogues (Figure 21a) [89], are other non-specific 
inflammasome inhibitors. They are able to decrease the activation of NLRP3, NLRP1, and AIM2 
inflammasomes in a NF-κB-independent manner. However, bromoxone also decreases pro-IL-1β 
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expression by interfering with the NF-κB pathway upstream of IKKβ-kinase. In the same work, 
Gong et al. identified 5Z-7-oxozeaneol (Figure 21b) as an NLRP3 inhibitor and found that it shares 
similar properties to bromoxone.  
 
 
 
Figure 21. a) Molecular structure of bromoxone and its analogues that have been identified as 
NLRP3 inhibitors; b) Molecular structure of 5Z-7-oxozeaneol. 
 
 
Several negative regulators, which either act directly or via the post-translational modification of 
the proteins that make up the NLRP3 inflammasomes, have been identified. As mentioned above, 
deubiquitinase BRCC3 plays an essential role as one of the negative regulators of the NLRP3 
inflammasome. 
In 2013, Py et al. discovered that G5 (4H-thiopyran-4-one, tetrahydro-3,5-bis[(4-
nitrophenyl)methylene]-1,1-dioxide; Figure 22), which is a non-selective isopeptidase inhibitor that 
was originally developed as an anticancer agent [162], was able to inhibit NLRP3 activation via the 
inhibition of BRCC3 activity [53]. G5 possess a cross-conjugated α,β-unsaturated dienone structure 
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bearing two sterically accessible electrophilic β-carbons, meaning that it can therefore act as a 
Michael acceptor for the targeting of nucleophiles, such as the catalytic cysteine of several 
isopeptidases. Its electrophilic properties mean that G5 is not selective for BCCR3 as it is also able 
to inhibit ubiquitin carboxy-terminal hydrolases UCHL1, UCHL5 and the ubiquitin-specific 
protease USP2 and USP18 as well [163]. 
GW 4064 (Figure 22) is a small molecule that is known as an agonist of the nuclear farnesoid X 
receptor (FXR), through which bile acids modulate glucose metabolism. Activation of the FXR 
receptor has recently been demonstrated to negatively modulate NLRP3 inflammasome activation, 
and TGR5 (a G-protein-coupled bile acid receptor). The connection between bile acids and 
inflammasome regulation is yet not completely understood [164,165] and the mechanism of NLRP3 
inhibition by GW4064 has not been well defined either. Liu et al. have reported on the inhibitory 
effect of GW4064 on LPS-induced ileum injury in mice, and suggested that a mechanism involving 
TLR4/MyD88 downregulation may be involved [166]. However, Xie et al. have demonstrated that 
GW 4064 can inhibit NLRP3 inflammasome activation in a FXR-independent manner, by 
decreasing the ubiquitination and oligomerisation of ASC without altering NLRP3 ubiquitination or 
preventing NLRP3-ASC interactions [164]. The administration of GW 4064 inhibited IL-1β and IL-
18 release in BMDMs, in a dose-dependent manner, without interacting with the priming step of 
NLRP3. Nevertheless, when GW 4064 was administrated before LPS, it also inhibited NF-κB 
activation.  
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Figure 22. Molecular structures of G5 and GW4064. 
 
 
Another interesting NLRP3 inhibitor is OLT1177 (3-methylsulfonylpropionitrile), which is also 
known as dapansutrile (Figure 23a). Marchetti et al. have recently demonstrated that this small 
molecule potently inhibits NLRP3 activation, as well as IL-1β and IL-18 release from human 
macrophages and neutrophils. OLT1177 directly inhibits NLRP3 ATPase activity and prevents 
NLRP3-ASC and NLRP3-caspase-1 interactions from occurring [167]. OLT1177 is currently under 
development as a drug by Olatec Therapeutics [168]. OLT1177 was proven to be safe in healthy 
volunteers and is now undergoing phase 2b clinical trials for possible development into a new drug 
for the treatment of osteoarthritis of the knee [169].  
Nitrile derivatives have already been successfully exploited as covalent drugs. An example can be 
found in saxagliptin, a marketed DPP-IV inhibitor that acts through the covalent binding of catalytic 
Ser630 in the protease binding pocket [170]. As OLT1177 is a nitrile derivative, it can react with 
biological nucleophiles, such as thiols, alcohols and amines in a Pinner-type reaction to form 
thioimidates, imidates and amidines, respectively [171,172]. Depending on the type of product 
generated, the covalent bond formed can be relatively unstable, leading to it either regenerating the 
parent compound, or being converted into other adducts via reaction with nearby nucleophiles 
(Figure 23b-d). The rate of hydrolysis/conversion depends on the biological microenvironment and 
the accessibility of the formed bond by water. Studies into the reactivity of the nitrile group in 
OLT1177 are currently not available and, consequently, a final classification of OLT1177 as a 
covalent/non-covalent or reversible/irreversible inhibitor is not possible. However, it is the opinion 
of this review’s authors that its potent NLRP3 inhibition may arise from covalent inhibition at the 
protein level. 
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Figure 23. a) Molecular structure of OLT1177; b-d) putative reaction pathways of OLT1177 with 
(b) sulphur-, (c) oxygen-, (d) and nitrogen-based nucleophiles. 
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An electrophilic natural ent-kaurane diterpenoid derivative, oridonin (Figure 24) which is isolated 
from Rabdosia rubescens, was demonstrated to inhibit NLRP3 signalling while this review was 
being prepared [173]. Oridonin was previously described as a 5'-adenosine monophosphate-
activated protein kinase (AMPK) inhibitor that can interfere with glucose metabolism and induce 
autophagy in colorectal cancer cells [174]. The action of oridonin on NLRP3 is mediated by 
covalent binding to Cys279 in the NACHT domain of NLRP3. This binding prevents the NLRP3-
NEK7 interaction from occurring and thereby inhibits NLRP3 activation and assembly. Oridonin is 
active at 20 mg/kg in mouse models of peritonitis and gouty arthritis, it also counteracts the 
inflammatory effect triggered with a HFD regimen when administered to mice at 3 mg/kg for six 
weeks restoring insulin sensitivity and decreasing intracellular lipid accumulation in liver [173].  
 
 
 
Figure 24. Molecular structure of oridonin. 
 
 
In table 1 we report a summary of in vitro data of selected molecules in order to help the reader 
having an overview about covalent NLRP3 inhibitors described in this review. Of note, in 
completing table 1 some data have been extrapolated from figures and graphs, therefore, little 
approximation might be present. 
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16. Concluding remarks  
The discovery of new agents that can block NLRP3 inflammasome signalling holds great promise for 
the development of a new class of anti-inflammatory and immunomodulatory drugs. This will thus 
pave the way for new pharmacological options for the treatment of numerous pathological conditions 
with unmet needs. The research of effective and selective NLRP3 inflammasome inhibitors is still a 
highly challenging task for biologists, pharmacologists and medicinal chemists. A great deal of 
progress has recently been made in the elucidation of NLRP3 activation and signalling mechanisms. 
However, there is still a lack of detail as to its molecular 3D structure, which thus complicates the 
discovery of drugs that can act directly on the protein target. 
Early observations suggested that the use of electrophilic compounds may be a good starting point 
from which to develop NLRP3 blocking agents [103]. Electrophilic compounds are able to 
covalently bind to cysteine-rich NLRP3, and thereby irreversibly or reversibly block target protein 
activity, depending on the electrophilic warhead employed. As described in this review, this 
strategy has proven to be generally successful, and numerous electrophilic NLRP3 inhibitors have 
been reported. However, the use of covalent inhibitors entails some precautions, because, even if 
their reactivity is appropriately tuned, they can give non-specific reactions with other nucleophiles 
in proteins. Most of the off-target interactions that occur with electrophilic NLRP3 inhibitors have 
been identified within the NF-κB and Keap1/Nrf2 pathways. From a therapeutic point of view this 
is not necessarily a disadvantage, as NF-kB inhibition can act synergically with NLRP3 inhibition 
and lead to enhanced anti-inflammatory activity in vivo.  
The discovery of new small molecules that act as covalent NLRP3 inhibitors must therefore take 
into account the possibility that interactions may occur with other targets. A recently proposed tool 
kit, which is made up of well-characterized molecules endowed with nanomolar potency against 
different points of the inflammasome pathway, can be of help in the discovery and biological 
validation of new small molecule acting as specific NLRP3 inhibitors [175]. Moreover, ligands 
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blocking NLRP3 through different mechanisms could help in investigating new hypothesis and look 
for the ideal inhibitory strategy. Non-covalent inhibitors (e.g. MCC950), covalent/non covalent 
inhibitors able to block NLRP3 ATPase activity (e.g. INF39, CY-09, OLT1177), and covalent 
inhibitors devoid of this last property (e.g. oridonin) might represent useful tools toward the choice 
of the best NLRP3 inhibition strategy in different contexts.  
There are no univocal winning strategies for the development of new covalent NLRP3 inhibitors. A 
possibility may be the development of targeted covalent inhibitors that are specific for NLRP3. 
However, this drug-design strategy is currently hampered by the limited structural knowledge that we 
have of the target. 
Another intriguing approach could be the inhibition of NLRP3 ATPase activity, as all the small 
molecules that inhibit it have shown an in-cell ability to prevent IL-1β release. When developing such 
a class of agents, allosteric inhibitors, rather than agents that compete with ATP for its binding pocket, 
would appear to be preferable if selective NLRP3 inhibitors are to be obtained.  
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Table 1. Summary of biological effects relevant to NLRP3 inflammasome inhibition for selected NLRP3 inhibitors described in this article. 
Compound 
(rev/irrev) 
Main mechanism of 
action 
Selectivity vs other 
inflammasomes 
IL-1β 
inhibition 
% (µM) 
NLRP3 
ATPase 
inhibition 
% (µM) 
Pyroptosis 
Inhibition 
% (µM) 
Other target(s)a Cytotoxicity 
TC50 ± SE 
(µM) 
Ref 
BAY 
(irrev) 
Inhibition of NLRP3 
ATPase  
Partial inhibition of 
NLRC4 
>80 % 
(10-100 µM)b 
60 %  
(10 µM) 
60 %  
(10 µM)b 
PTPs; IKKβ;  1.5 ± 0.3c 
 
[88] 
[97-100] 
[102] [167] 
MNS 
(irrev) 
Inhibition of NLRP3 
ATPase  
selective 2 –100 %  
(0.5–10 µM)b 
35–75 % 
(1–10 µM) 
85 % 
(5 µM)b 
Syk and Src 
kinases 
3.2 ± 0.8c 
 
[90] 
[102] 
INF39 
(irrev) 
Inhibition of NLRP3 
ATPase 
NT 60-80 % 
(10-100 µM)b 
29-52 % 
(50-100 µM) 
34 % d 
(10 µM) 
NF-kB Non toxic up 
to 100 µMc 
[102] 
INF58 
(irrev) 
Inhibition of NLRP3 
ATPase 
NT 65 % 
(20 µM)b 
50 % 
(74 µM) 
10-64 % d 
(1-100 µM) 
- Non toxic up 
to 100 µMc 
[95] 
NBC6 
(irrev) 
Inhibition of NLRP3 
assembly 
Selective  
up to 10 µM. AIM2 
also targeted at 
higher conc. 
99 % 
(10 µM)e 
NT NT - Non toxic up 
to 100 µMf 
[110] [111] 
CY-09 
(rev ?) 
Inhibition of NLRP3 
ATPase 
selective 40–85 % 
(1–10 µM)b 
40–85 % 
(0.1–1 µM) 
80 %  
(10 µM)g 
- Not reported [113] 
[173] 
DiMF 
(irrev) 
Unknown; multiple 
targets ? 
NT 20–65 %  
(0.1–10 µM)d 
inactive 65 % 
(10 µM)d 
Keap-1/NRF2; 
HCA2 ? 
95.5 ± 1.2c 
 
[102] 
[125] [126] 
Tranilast 
(irrev ?) 
Inhibition of NLRP3-
NLRP3 and NLRP3-
ASC interactions 
selective 75 % 
(100 µM)d 
inactive inactive NF-κB pathway Not reported [130] [131] 
BOT-4-one 
(irrev) 
Inhibition of NLRP3 
ATPase 
Partial inhibition of 
NLRC4 
35-99 % 
(0.75–3 µM)b 
50–80 %  
(1.5–3 µM) 
35-99 % 
(0.75–3 µM)b 
IKKβ; NF-κB Akt 
signaling; NLRP3 
ubiquitinylation 
Non toxic up 
to 3 µMc 
[134] [135] 
WP1066 
(irrev ?) 
Unknown; Alkylation 
of NLRP3 ? 
NT 80–100 % 
(1–10 µM)h 
NT 99 % 
(10 µM)e 
JAK-STAT3  <10 µMc 
 
[140] 
CAPE 
(irrev ?) 
Block of NLRP3-
ASC interaction 
Partial inhibition of 
AIM2 
30-100 % 
(0.5–10 µM)b 
NT NT NF-kB Non toxic up 
to 10 µMi 
[142] 
ILG 
(irrev ?) 
Unknown selective 70–95 % 
(1-10 µM)b 
NT inactive TLR4/MD-2; 
NF-κB; MAPK; 
JNK1/2 
Non toxic up 
to 10 µMi 
[153] 
SFN 
(irrev ?) 
unknown NLRP1, NLRC4 
AIM2 ?  
100 % 
(5–50 µM)b by 
Western blot 
NT 100 % 
NLRP1-
mediated 
pyroptosis  
(100 µM) 
Keap1/NRF2; 
TLR4 
Non toxic up 
to 100 µMi 
[154] [155] 
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Br 
(irrev) 
Multiple targets AIM2, NLRP1 50 % 
(0.17 µM)d 
NT 85 %  
(2.5 µM)d 
NF-kB Non toxic at 
2.5 µMc 
[89] 
Parth 
(irrev) 
NF-κB / NLRP3 / 
caspase-1 axis 
Non selective 
NLRP1, NLRC4, 
AIM2 
20-100 % 
(0.01-10 µM)d 
23 % 
(10 µM) 
80 % 
(1–20 µM)b 
NF-κB (IKKβ, 
p65); Caspase-1 
20.1 ± 5.5l 
 
[88] [103] 
[125] 
OLT1177 
(rev ?) 
Inhibition of NLRP3 
ATPase; block of 
NLRP3-ASC, 
NLRP3-caspase 1 
interactions, block of 
NLRP3 assembly 
selective 60 % 
(0.0001-10 
µM)m 
60 % 
(1 µM) 
25–40 % 
(0.001–10 µM)m 
Src; Fyn; HcK; 
STAT3; NF-kB (in 
vivo) 
Non toxic in 
healthy 
volunteers 
up to 1 g/kg 
[167] 
Oridonin 
(irrev) 
Block of NLRP3-
NEK7, NLRP3-ASC 
interactions, NLRP3 
assembly 
selective 100 % 
(2µM)b 
 
inactive 70-95 % 
(0.5–2µM)g 
NF-κB; 
MAPK 
 
Not reported [173] 
a Direct effects reported in literature are written in plain text, when experimental data cannot discriminate between direct or downstream effects, italic is used; bin 
LPS/ATP-stimulated BMDMs; cin THP-1 cells; din PMA-treated and LPS/ATP-stimulated THP-1; ein PMA-treated and LPS/nigericin-stimulated THP-1; fin 
HEK293 and HepG2 cells; gin LPS/nigericin-stimulated BMDMs;  hin PMA-treated and LPS/imiquimod-stimulated THP-1; iin BMDMs; lin HK-2 cells; min 
LPS/ATP-stimulated murine macrophages J774A.1 
Abbreviations: irrev= irreversible; rev = reversible; NT = not tested; SFN = sulforaphane; ILG = isoliquiritigenin; parth = partrhenolide; BAY = BAY 11-7082; 
Br = bromoxone; DiMF = dimethylfumarate; PTPs = protein tyrosine phosphatases; IKK = inhibitor of nuclear factor kappa-B kinase; HCA2 = hydroxyl 
carboxylic acid receptor 2; NF-κB = Nuclear factor kappaB; MAPK = Mitogen-activated protein kinase; TLR4 = Toll-like receptor4; Keap1/NRF2 = Kelch-like 
ECH-associated protein 1/ Nuclear factor (erythroid-derived 2)-like 2; STAT3 = signal transducer and activator of transcription protein3; Src = Proto-oncogene 
tyrosine-protein kinase Src; Fyn = Proto-oncogene tyrosine-protein kinase Fyn; HcK = Tyrosine-protein kinase HCK ; JNK1/2 = c-Jun N-terminal kinase 1/2; 
JAK = Janus kinase; IKKβ = inhibitor of nuclear factor kappa-B kinase subunit beta; Akt = AKT serine/threonine kinase. 
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